Loading
Life sciences · Journal article
Gene Therapy · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
CRISPR/Cas9-mediated gene editing targeting the BCL11A erythroid enhancer has transformed therapeutic approaches for transfusion-dependent β-thalassemia (β-thal) and sickle cell disease (SCD). Even though clinical efficacy is well demonstrated, translating these therapies to global patient populations requires a strong evidence-based framework to address critical concerns regarding long-term genotoxic safety and long-lasting engraftment dynamics. Following the 2020 PRISMA guidelines, we conducted a systematic review of 21 key clinical and preclinical studies (published during 2014–2026) to evaluate CRISPR/Cas9-mediated gene editing in β-thal and SCD. The inclusion criteria focused on studies reporting foetal haemoglobin (HbF) induction, transfusion independence (TI) and safety outcomes. Clinical data indicate high efficacy, with exagamglogene autotemcel (exa-cel) achieving TI in 91% of β-thal patients and a vaso-occlusive crisis (VOC)-free status in 97% of SCD patients. Safety profiling confirmed that severe adverse events, including febrile neutropenia and stomatitis, are primarily associated with busulfan-based myeloablation rather than gene editing. Gene-editing safety and conditioning toxicity are interlinked because conditioning is part of the process, and edited clones might interact with stress pathways during long-term repopulation. Preclinical benchmarks substantiate molecular reliability, with negligible off-target activity reported in most validated platforms. However, rare instances of complex structural rearrangements and intergenic off-target indels highlight the necessity for in-depth, unbiased long-term genomic surveillance. CRISPR/Cas9 therapeutics for β-thal and SCD treatment constitute a treatment option within current clinical frameworks. These therapies need continuous surveillance. Rather than establishing a perfect plan, this systematic review highlights that while current platforms are thought to have short-term molecular precision, the use of Multilayer Safety Risks Screening and Surveillance for pretransplant conditioning is critical. This approach helps address long-term genotoxic concerns and ensures the safety and scalability of gene-editing therapies for global β-thal and SCD patient care.